France's NASH con­tender Gen­fit leaps on­to Nas­daq with $135M IPO

As it gears up for the late-stage read­out of its lead ex­per­i­men­tal NASH drug, France’s Gen­fit is vault­ing on­to the Nas­daq on Wednes­day with a $135 mil­lion IPO un­der the sym­bol $GN­FT.

The Lille-based com­pa­ny, which is al­ready list­ed on Eu­ronext Paris al­so as $GN­FT, spelled out the terms of the of­fer­ing on Tues­day.

The com­pa­ny de­cid­ed it want­ed a US list­ing to ex­pand its base in Boston, ac­cess the US tal­ent pool — con­sid­er­ing the ge­og­ra­phy is go­ing to be a large mar­ket for the drug (elafi­bra­nor) — as well a forge a clos­er con­nec­tion with US in­vestors, Gen­fit COO Dean Hum told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER